Archive for December 2014
Does it take two or four to tango? Modeling & simulation of bispecific antibodies in oncology
Steeg T.v., Bergmann K., huang Q., Sachsenmeier K. and Agoram B., Does it take two or four to tango? Modeling & simulation of bispecific antibodies in oncology. Noordwijkerhout.(2014)
Read MoreCharacterization and prediction of cardiovascular effects of S1P receptor agonists
Snelder N., Ploeger B., Luttringer O., Rigel D., Webb R., Feldman D., Fu F., Beil M., Jin L., stanski D. and Danhof M., Characterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach. Noordwijkerhout.(2014)
Read MoreCharacterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach
Snelder N., Ploeger B., Luttringer O., Rigel D., Webb R., Feldman D., Fu F., Beil M., Jin L., stanski D. and Danhof M., Characterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach. Noordwijkerhout.(2014)
Read MoreMechanism based PK/PD model for the effect of rhLCAT and apoA-I preparations
Bergmann K., Fairman D. and Vis P., Mechanism based PK/PD model for the effect of rhLCAT and apoA-I preparations on reverse cholesterol transport. Noordwijkerhout.(2014)
Read MoreA systems pharmacology model accounting for tracer dynamics throughout the APP pathway
Maanen E.v., Steeg T.v., Stone J., Dobrowolska J., Michener M., Savage M., Kennedy M., Bateman R., Kleijn H. and Danhof M., A systems pharmacology model accounting for tracer dynamics throughout the APP pathway: Implications for interpretation of BACE inhibition response in CMP rhesus monkeys. Noordwijkerhout.(2014)
Read MoreIntegrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model
Maanen E.v., Steeg T.v., Stone J., Dobrowolska J., Michener M., Savage M., Kennedy M., Bateman R., Kleijn H. and Danhof M., Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys., PAGE.(2014) [Link to publication]
Read MoreA new model-based approach to compare toxicity of a series of compounds
Maanen E.v., Ackaert O., Haddish-Berhane N., Snelder N., Jongh J.d., Barton H. and Betts A., A new model-based approach to compare toxicity of a series of compounds based on their categorical toxicity scores. PAGE.(2014) [Link to publication]
Read MoreQuantification of the effect of AZD5213
Ackaert O., Steeg T.v., Hannesdottir K., Alexander R., Raudibaugh K., Kugler A. and Vis P., Quantification of the effect of AZD5213 on sleep in patients with Alzheimer’s disease or mild cognitive impairment using a two-state Markov model. PAGE.(2014) [Link to publication]
Read MoreEvaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin
Stringer F., DeJongh J., Enya K., Koumura E., Danhof M. and Kaku K., Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin for Pioglitazone in Japanese Patients with Type 2 Diabetes, Diabetes Technol Ther, 22: 22, 2014. [Link to publication]
Read MoreTranslational Pharmacokinetic Modeling of Fingolimod
Snelder N., Ploeger B.A., Luttringer O., Stanski D.R. and Danhof M., Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-mediated Phosphorylation, Drug Metab Dispos, 25(113): 056770, 2014. [Link to publication]
Read More